Biotech
Freenome
Freenome raises $254M Series D at $1.2B valuation
$254M
Total Raised
Series D
Latest Round
2014
Founded
300+
Employees
South San Francisco, CA
1 min read
Quick Facts
Valuation
$1.2B
Latest Round Size
$254M
Latest Round Date
February 2024
Freenome: Series D Funding Round
Freenome has successfully raised $254M in Series D funding, reaching a valuation of $1.2B.
Company Overview
Multi-cancer early detection blood test developer using AI
Funding Details
The Series D round was led by Roche, with participation from a16z Life Sciences, ARK Investments.
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2014
- Employees: 300+
- Category: Biotech
Investment
Freenome plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Roche: Verified investor in Series D
- a16z Life Sciences: Verified investor in Series D
- ARK Investments: Verified investor in Series D
Key Investors
Roche
Lead Investor
Verified investor in Series D
a16z Life Sciences
Investor
Verified investor in Series D
ARK Investments
Investor
Verified investor in Series D
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M